Cargando…
Enhancer of Zeste Homolog 2 as an Independent Prognostic Marker for Cancer: A Meta-Analysis
BACKGROUND: Novel biomarkers are of particular interest for predicting cancer prognosis. This study aimed to explore the associations between enhancer of zeste homolog 2 (EZH2) and patient survival in various cancers. METHODS: Relevant literature was retrieved from PubMed and Web of Science database...
Autores principales: | Chen, Shuling, Huang, Lixia, Sun, Kaiyu, Wu, Dexi, Li, Minrui, Li, Manying, Zhong, Bihui, Chen, Minhu, Zhang, Shenghong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431777/ https://www.ncbi.nlm.nih.gov/pubmed/25974088 http://dx.doi.org/10.1371/journal.pone.0125480 |
Ejemplares similares
-
Long Noncoding RNA HOTAIR as an Independent Prognostic Marker in Cancer: A Meta-Analysis
por: Zhang, Shenghong, et al.
Publicado: (2014) -
Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma
por: Ho, Thai Huu, et al.
Publicado: (2017) -
Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma
por: Wagener, Nina, et al.
Publicado: (2010) -
Patients with Gastric Polyps need Colonoscopy Screening at Younger Age: A Large Prospective Cross-Sectional Study in China
por: Zhang, Shenghong, et al.
Publicado: (2019) -
Enhancer of zeste homolog 2 is involved in the proliferation of endometrial carcinoma
por: JIA, NAN, et al.
Publicado: (2014)